// App-Quantinova.ai

ABS139 : LONGER‐TERM EFFICACY AND SAFETY OF CONCIZUMAB PROPHYLAXIS IN PATIENTS WITH SEVERE HAEMOPHILIA A WITHOUT INHIBITORS: RESULTS FROM THE EXTENSION PART OF THE PHASE 2 EXPLORER5 TRIAL

Researchers

Presenter

  • H. Eichler

Principal Investigators

  • P. Angchaisuksiri

  • J. Astermark

  • G. Benson

  • K. Cepo

  • P. Chowdary

  • T. Hansen

  • K. Kavakli

  • A. P. Wheeler

  • J. Oldenburg

Medical Centers

  • Institute of Clinical Hemostaseology and Transfusion Medicine, Saarland University and University Hospital, Homburg/Saar, Germany

  • Division of Gastroenterology and Hepatology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

  • Department of Translational Medicine‐Clinical Coagulation, Lund University, Malmö, Sweden

  • Department of Gastroenterology, Belfast Health and Social Care Trust, Belfast, United Kingdom

  • Novo NordiskA/S, Soborg, Denmark

  • Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free London NHS Foundation Trust, London, United Kingdom

  • Ege University Childrens Hospital, Izmir,Turkey

  • Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN

  • Department of Immunohematology and Department of Molecular Haemostasis, Institute of Transfusion Medicine and Immunohematology, University Hospital, Bonn, Germany

Locations

  • Germany

  • Thailand

  • Sweden

  • United Kingdom

  • Denmark

  • Turkey

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • Tissue factor pathway inhibitor

Drug/Treatment

  • NN7415

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • II

Study Id's

  • NCT03196297

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved